[1] UNAIDS. Global HIV & AIDS statistics — Fact sheet. 2024. https://www.unaids.org/en/resources/fact-sheet. [2025-9-15].
[2] Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, et al. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastroenterol Belg 2021;84(4):637 − 56. https://doi.org/10.51821/84.4.015.
[3] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis. 2016. https://www.who.int/publications/i/item/WHO-HIV-2016.06. [2025-9-17].
[4] United Nations. Political declaration on HIV and AIDS: ending inequalities and getting on track to end AIDS by 2030. 2021. https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf. [2025-9-25].
[5] Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016;16(7):797 − 808. https://doi.org/10.1016/S1473-3099(15)00485-5.
[6] Jordan AE, Perlman DC, Neurer J, Smith DJ, Des Jarlais DC, Hagan H. Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis. Int J STD AIDS 2017;28(2):145 − 59. https://doi.org/10.1177/0956462416630910.
[7] Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV cohort study. Lancet 2000;356(9244):1800 − 5. https://doi.org/10.1016/s0140-6736(00)03232-3.
[8] Zhang FJ, Zhu H, Wu YS, Dou ZH, Zhang Y, Kleinman N, et al. HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study. Lancet Infect Dis 2014;14(11):1065 − 72. https://doi.org/10.1016/S1473-3099(14)70946-6.
[9] Ma Y, Zhao DC, Yu L, Bulterys M, Robinson ML, Zhao Y, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010;50(2):264 − 71. https://doi.org/10.1086/649215.
[10] Weis N, Lindhardt BO, Kronborg G, Hansen ABE, Laursen AL, Christensen PB, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006;42(10):1481 − 7. https://doi.org/10.1086/503569.